SLC5A2 and atrial fibrillation: Mechanistic studies show that SGLT2 inhibitors could inhibit the sodium–hydrogen exchange in cardiac myocytes, which may ameliorate myocardial remodeling and, thus, reduce the risk of AF (Arow et al., 2020; Cowie and Fisher, 2020).